BR112015015523A2 - composição de vacina nasal para influenza - Google Patents

composição de vacina nasal para influenza

Info

Publication number
BR112015015523A2
BR112015015523A2 BR112015015523A BR112015015523A BR112015015523A2 BR 112015015523 A2 BR112015015523 A2 BR 112015015523A2 BR 112015015523 A BR112015015523 A BR 112015015523A BR 112015015523 A BR112015015523 A BR 112015015523A BR 112015015523 A2 BR112015015523 A2 BR 112015015523A2
Authority
BR
Brazil
Prior art keywords
influenza
vaccine composition
nasal vaccine
nasal
adjuvant
Prior art date
Application number
BR112015015523A
Other languages
English (en)
Other versions
BR112015015523B1 (pt
Inventor
Ainai Akira
Hasegawa Hideki
Suzuki Tadaki
Kamishita Taizou
Miyazaki Takashi
Original Assignee
Japan As Represented By Director General Of Nat Institute Of Infectious Diseases
Toko Yakuhin Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan As Represented By Director General Of Nat Institute Of Infectious Diseases, Toko Yakuhin Kogyo Kk filed Critical Japan As Represented By Director General Of Nat Institute Of Infectious Diseases
Publication of BR112015015523A2 publication Critical patent/BR112015015523A2/pt
Publication of BR112015015523B1 publication Critical patent/BR112015015523B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

resumo patente de invenção: "composição de vacina nasal para influenza". a presente invenção refere-se a uma composição de vacina para a influenza para administração por pulverização na mucosa nasal a qual compreende um vírion de influenza total inativado e um material à base de gel compreendendo carbóxi vinil polímero, que é caracterizado por não compreender um adjuvante.
BR112015015523-5A 2012-12-28 2013-10-23 Composição de vacina nasal para influenza BR112015015523B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012-287900 2012-12-28
JP2012287900 2012-12-28
PCT/JP2013/078721 WO2014103488A1 (ja) 2012-12-28 2013-10-23 経鼻インフルエンザワクチン組成物

Publications (2)

Publication Number Publication Date
BR112015015523A2 true BR112015015523A2 (pt) 2017-07-11
BR112015015523B1 BR112015015523B1 (pt) 2023-02-23

Family

ID=51020588

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015015523-5A BR112015015523B1 (pt) 2012-12-28 2013-10-23 Composição de vacina nasal para influenza

Country Status (27)

Country Link
US (2) US20160015800A1 (pt)
EP (2) EP2939692B1 (pt)
JP (1) JP6247639B2 (pt)
KR (1) KR102071099B1 (pt)
CN (2) CN110038123A (pt)
AU (1) AU2013367751B2 (pt)
BR (1) BR112015015523B1 (pt)
CA (1) CA2894223C (pt)
CY (1) CY1122372T1 (pt)
DK (1) DK2939692T3 (pt)
ES (1) ES2731899T3 (pt)
HK (1) HK1209646A1 (pt)
HU (1) HUE044434T2 (pt)
IL (1) IL239284B (pt)
LT (1) LT2939692T (pt)
MX (1) MX371154B (pt)
MY (1) MY173503A (pt)
NZ (1) NZ708922A (pt)
PH (1) PH12015501482A1 (pt)
PL (1) PL2939692T3 (pt)
PT (1) PT2939692T (pt)
RU (1) RU2652296C2 (pt)
SG (2) SG11201504648TA (pt)
SI (1) SI2939692T1 (pt)
TR (1) TR201910293T4 (pt)
TW (1) TWI624280B (pt)
WO (1) WO2014103488A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5762307B2 (ja) * 2009-03-31 2015-08-12 国立感染症研究所長 経鼻投与用ワクチンを用いるインフルエンザの予防方法
US9457077B2 (en) 2009-11-18 2016-10-04 Katherine Rose Kovarik Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
US9408880B2 (en) 2013-12-20 2016-08-09 Katherine Rose Kovarik Method and system for prevention and treatment of allergic and inflammatory diseases
US9585920B2 (en) 2011-02-04 2017-03-07 Katherine Rose Kovarik Method and system for treating cancer cachexia
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11103453B2 (en) 2014-06-25 2021-08-31 Toko Yakuhin Kogyo Kabushiki Kaisha Rhinovaccination system of influenza vaccine
JP6322844B2 (ja) 2014-06-25 2018-05-16 東興薬品工業株式会社 医療用シリンジに用いられる点鼻用噴霧ノズル
CN105342982B (zh) * 2015-11-19 2018-08-28 上海现代药物制剂工程研究中心有限公司 经鼻给药的流感疫苗免疫制剂及其制备方法
CN108289948A (zh) * 2015-11-27 2018-07-17 日东电工株式会社 口腔内给药用疫苗药物组合物和口腔内给药用疫苗药物组合物的制造方法
WO2018021889A1 (ko) * 2016-07-29 2018-02-01 주식회사 셀투인 점막용 항인플루엔자 바이러스 조성물
TWI811248B (zh) * 2017-10-05 2023-08-11 日商東興藥品工業股份有限公司 經鼻ｂ型肝炎疫苗組成物及其製造方法
MX2021016040A (es) 2019-07-03 2022-03-11 Aillis Inc Composicion farmaceutica para el tratamiento de infecciones de virus de influenza.
CN113117093B (zh) * 2019-12-31 2024-02-09 辽宁成大生物股份有限公司 一种适用于鼻粘膜递送流感疫苗的促进剂
WO2023120535A1 (ja) * 2021-12-20 2023-06-29 東興薬品工業株式会社 ポリアクリル酸系ポリマーを含有するワクチンアジュバント剤およびその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158761A (en) * 1989-04-05 1992-10-27 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
US5215739A (en) * 1989-04-05 1993-06-01 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
JPH0678245B2 (ja) * 1989-07-04 1994-10-05 東興薬品工業株式会社 鼻腔内噴霧投与用インフルエンザワクチンゲル製剤
PE20061428A1 (es) * 2005-03-23 2007-01-16 Glaxosmithkline Biolog Sa Formulacion de vacuna que comprende un adyuvante de emulsion aceite en agua y 3d-mpl
SI2011467T1 (sl) 2006-04-21 2021-01-29 Toko Yakuhin Kogyo Kabushiki Kaisha Posoda za tekočino in brezzračni sistem za razdeljevanje tekočine
HUE036777T2 (hu) * 2006-04-21 2018-07-30 Toko Yakuhin Kogyo Kk Bõrhöz/nyálkahártyához tapadó porlasztható gél típusú preparátum és adagolási rendszer a preparátum alkalmazásával
JP5762307B2 (ja) * 2009-03-31 2015-08-12 国立感染症研究所長 経鼻投与用ワクチンを用いるインフルエンザの予防方法

Also Published As

Publication number Publication date
PH12015501482B1 (en) 2015-09-21
EP2939692B1 (en) 2019-04-24
US20190091324A1 (en) 2019-03-28
KR102071099B1 (ko) 2020-01-29
CN104884086A (zh) 2015-09-02
US20160015800A1 (en) 2016-01-21
AU2013367751B2 (en) 2018-02-08
BR112015015523B1 (pt) 2023-02-23
CA2894223A1 (en) 2014-07-03
MX371154B (es) 2020-01-20
MX2015008380A (es) 2016-03-15
ES2731899T3 (es) 2019-11-19
CN110038123A (zh) 2019-07-23
DK2939692T3 (da) 2019-07-08
SG10201705190TA (en) 2017-07-28
RU2015130634A (ru) 2017-02-01
TW201427724A (zh) 2014-07-16
PT2939692T (pt) 2019-06-27
JPWO2014103488A1 (ja) 2017-01-12
EP2939692A4 (en) 2016-07-06
JP6247639B2 (ja) 2017-12-13
PL2939692T3 (pl) 2019-10-31
NZ708922A (en) 2019-10-25
AU2013367751A8 (en) 2015-08-27
SI2939692T1 (sl) 2019-10-30
PH12015501482A1 (en) 2015-09-21
AU2013367751A1 (en) 2015-07-09
MY173503A (en) 2020-01-29
KR20150102995A (ko) 2015-09-09
TWI624280B (zh) 2018-05-21
TR201910293T4 (tr) 2019-07-22
IL239284A0 (en) 2015-07-30
WO2014103488A1 (ja) 2014-07-03
SG11201504648TA (en) 2015-07-30
EP2939692A1 (en) 2015-11-04
EP3566715A1 (en) 2019-11-13
HK1209646A1 (en) 2016-04-08
LT2939692T (lt) 2019-08-12
HUE044434T2 (hu) 2019-10-28
RU2652296C2 (ru) 2018-04-25
CY1122372T1 (el) 2021-01-27
IL239284B (en) 2020-02-27
CA2894223C (en) 2021-04-06

Similar Documents

Publication Publication Date Title
BR112015015523A2 (pt) composição de vacina nasal para influenza
CL2017003288A1 (es) Métodos para tratar o prevenir enfermedades relacionadas con el colesterol (divisional solicitud 201303214)
BR112014003903A2 (pt) composições dentais que compreendem agentes de adição fragmentação
BR112013022397A2 (pt) vacinas combinadas com doses menores de antígeno e/ou adjuvante
BR112015012197A2 (pt) terapia de combinação
BR112013031268A8 (pt) polipeptídeos
BR112015022972A2 (pt) composição farmacêutica de cloridrato de s-cetamina
CO6551750A2 (es) Vacuna del virus del dengue inactivado que incluye un adyuvante sin aluminio
CL2018002692A1 (es) Vacuna bivalente contra el virus de gripe porcina.(divisional solicitud 201701961)
BR112013020743A2 (pt) composições e métodos para a terapia e diagnóstico de influenza
BR112015011430A2 (pt) composição para liberação imediata e prolongada
CL2017003066A1 (es) Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal
BR112015012841A2 (pt) composição imunogênica, vacina, e, uso de uma composição imunogênica
BR112015009989A2 (pt) estabilizante para a hialuronidase e formulação líquida que compreende hialuronidase
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
BR112015021523A2 (pt) composição de uma vacina contra a tosse convulsa acelular, e, métodos para vacinar um sujeito contra a bordetella pertussis e para proteger um sujeito da tosse convulsa
PH12016502529B1 (en) Influenza vaccine nasal vaccination system
BR112014023092A8 (pt) Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit
BR112013023354A2 (pt) vacina para rinite equina
NZ580603A (en) Intradermal influenza vaccine
BR112017013373A2 (pt) anestésico à base de tetracaína.
CU20120115A7 (es) Composición farmacéutica sólida para administración bucal de agomelatina
BR112022008711A2 (pt) Métodos para produzir uma vacina viral e reduzir o tamanho da partícula viral
UY35294A (es) Composición farmacéutica sólida para administración bucal de agomelatina
BR112022011850A2 (pt) Vacina respiratória oral

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/10/2013, OBSERVADAS AS CONDICOES LEGAIS